Contineum Therapeutics, Inc.
CTNM
28 insider filings · Latest: Jul 8, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | Feb 26 9:40 PM | Carmine N. StengoneDirector, CEO and President | Sale | 2,700 | $16.02 | $43.2K | 14,954(D) | View → |
| Feb 24, 2026 | Feb 26 9:40 PM | Carmine N. StengoneDirector, CEO and President | Sale | 4,400 | $16.02 | $70.5K | 14,954(D) | View → |
| Feb 25, 2026 | Feb 26 9:39 PM | Daniel S. LorrainChief Scientific Officer | Sale | 3,824 | $16.01 | $61.2K | 156,052(D) | View → |
| Feb 24, 2026 | Feb 26 9:39 PM | Daniel S. LorrainChief Scientific Officer | Sale | 4,300 | $16.03 | $68.9K | 156,052(D) | View → |
| Feb 19, 2026 | Feb 20 9:05 PM | Daniel S. LorrainChief Scientific Officer | Sale | 100 | $16.00 | $1.6K | 156,052(D) | View → |
| Feb 11, 2026 | Feb 13 9:27 PM | Carmine N. StengoneDirector, CEO and President | Sale | 400 | $16.00 | $6.4K | 14,954(D) | View → |
| Feb 11, 2026 | Feb 13 9:26 PM | Daniel S. LorrainChief Scientific Officer | Sale | 400 | $16.00 | $6.4K | 156,052(D) | View → |
| Feb 11, 2026 | Feb 11 9:29 PM | DANIEL LORRAIN | Proposed Sale | 16,050 | $15.75 | $252.8K | — | View → |
| Feb 11, 2026 | Feb 11 9:29 PM | CARMINE STENGONE | Proposed Sale | 7,500 | $15.75 | $118.1K | — | View → |
| Feb 3, 2026 | Feb 5 9:24 PM | Daniel S. LorrainChief Scientific Officer | Sale | 4,170 | $14.94 | $62.3K | 156,052(D) | View → |
| Feb 3, 2026 | Feb 3 9:32 PM | DANIEL LORRAIN | Proposed Sale | 4,170 | $14.38 | $60.0K | — | View → |
| Jan 28, 2026 | Jan 30 9:52 PM | Tim WatkinsCMO & Head of Development | Sale | 3,611 | $14.18 | $51.2K | 0(D) | View → |
| Jan 5, 2026 | Jan 5 9:42 PM | DANIEL LORRAIN | Proposed Sale | 4,170 | $11.39 | $47.5K | — | View → |
| Dec 29, 2025 | Dec 29 9:25 PM | TIMOTHY WATKINS | Proposed Sale | 10,833 | $12.41 | $134.4K | — | View → |
| Dec 23, 2025 | Dec 23 9:20 PM | DANIEL LORRAIN | Proposed Sale | 4,170 | $12.26 | $51.1K | — | View → |
| Nov 18, 2024 | Nov 18 10:05 PM | DANIEL LORRAIN | Proposed Sale | 26,370 | $17.21 | $453.8K | — | View → |
← Previous
Page 2 of 2
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Feb 11, 2026 | Feb 13 9:27 PM | Carmine N. StengoneDirector, CEO and President | Option Exercise | 400 | $1.26 | 128,017(D) | View → |
| Feb 11, 2026 | Feb 13 9:26 PM | Daniel S. LorrainChief Scientific Officer | Option Exercise | 400 | $1.01 | 75,530(D) | View → |
| Jan 30, 2026 | Jan 30 9:59 PM | John Stephen HealyGeneral Counsel and Corp Sec | Grant/Award | 206,411 | $14.26 | 206,411(D) | View → |
| Jan 30, 2026 | Jan 30 9:57 PM | Peter T SloverChief Financial Officer | Grant/Award | 192,000 | $14.26 | 192,000(D) | View → |
| Jan 30, 2026 | Jan 30 9:56 PM | Carmine N. StengoneDirector, CEO and President | Grant/Award | 445,000 | $14.26 | 445,000(D) | View → |
| Jan 30, 2026 | Jan 30 9:54 PM | Daniel S. LorrainChief Scientific Officer | Grant/Award | 166,500 | $14.26 | 6,500(I) | View → |
| Jan 30, 2026 | Jan 30 9:52 PM | Tim WatkinsCMO & Head of Development | Grant/Award | 160,000 | $14.26 | 160,000(D) | View → |
| Jan 28, 2026 | Jan 30 9:52 PM | Tim WatkinsCMO & Head of Development | Option Exercise | 3,611 | $4.50 | 252,778(D) | View → |
← Previous
Page 2 of 2